CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $28.94M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 4.17: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
307.34MUSDvs all stocks (USD)
Revenue (TTM)
28.94MUSDvs all stocks (USD)
Profit Margin
-187.59%vs Biotechnology peers
Beta
1.17xvs all stocks
52-Week Change
7.07%vs all stocks
Market Capitalization
307.34MUSDvs all stocks (USD)
Enterprise Value
277.94MUSDvs all stocks (USD)
Forward P/E
-6.57xvs Biotechnology peers
Price to Sales (TTM)
10.62xvs Biotechnology peers
Price to Book (MRQ)
1.17xvs Biotechnology peers
Enterprise to Revenue
9.60xvs Biotechnology peers
Enterprise to EBITDA
-8.31xvs Biotechnology peers
Gross Margin
99.90%vs Biotechnology peers
Profit Margin
-187.59%vs Biotechnology peers
Operating Margin
-54.27%vs Biotechnology peers
Return on Assets (TTM)
-11.32%vs Biotechnology peers
Return on Equity (TTM)
-20.25%vs Biotechnology peers
Revenue (TTM)
28.94MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2430USDUpdated Jul 19, 2026Quarterly Revenue Growth
247.30%vs Biotechnology peers
Gross Profit (TTM)
28.62MUSDvs all stocks (USD)
EBITDA (TTM)
-33.44MUSDvs all stocks (USD)
Net Income (TTM)
-54.29MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
247.30%vs Biotechnology peers
Operating Cash Flow (TTM)
-25.50MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.57MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
18.67MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
303.00KUSDFY2025 · Dec 31, 2025Gross Profit
18.36MUSDFY2025 · Dec 31, 2025Operating Income
-68.97MUSDvs all stocks (USD)
Pre-tax Income
-66.29MUSDFY2025 · Dec 31, 2025Income Tax Expense
-1.51MUSDFY2025 · Dec 31, 2025Net Income
-64.78MUSDFY2025 · Dec 31, 2025EBIT
-68.97MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-47.22MUSDFY2025 · Dec 31, 2025Research & Development
47.75MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
29.21MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-2.55MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.66MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.5700USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.5700USDFY2025 · Dec 31, 2025Basic Shares Outstanding
113.64MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
113.64MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-64.78MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-31.49MUSDFY2025 · Dec 31, 2025Free Cash Flow
-32.05MUSDDerived from operating cash flow minus capital expenditure. This filing charges 21.75M of depreciation against 565K of capital expenditure, and its own free-cash-flow line reads -37.02M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
26.08MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-64.78MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
21.75MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-1.53MUSDFY2025 · Dec 31, 2025Stock-based Compensation
15.82MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.09MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
189.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-231.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.80MUSDFY2025 · Dec 31, 2025Capital Expenditures
-565.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-46.86MUSDFY2025 · Dec 31, 2025Sale of Investments
50.89MUSDFY2025 · Dec 31, 2025Other Investing Activity
3.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
6.47MUSDFY2025 · Dec 31, 2025Other Financing Charges
-774.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
27.43MUSDFY2025 · Dec 31, 2025Shares Outstanding
144.78MSharesUpdated Jul 19, 2026Float Shares
113.85MSharesUpdated Jul 19, 2026Shares Short
4.75MSharesUpdated Jul 19, 2026Short Ratio
7.82daysvs all stocks
Short % of Shares Outstanding
3.60%vs all stocks
% Held by Insiders
15.33%vs all stocks
% Held by Institutions
50.97%vs all stocks
Total Cash (MRQ)
49.07MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.3380USDUpdated Jul 19, 2026Total Debt (MRQ)
19.67MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0749xvs Biotechnology peers
Current Ratio (MRQ)
4.80xvs Biotechnology peers
Book Value per Share (MRQ)
1.81USDUpdated Jul 19, 2026Total Assets
300.91MUSDvs all stocks (USD)
Total Current Assets
65.34MUSDFY2025 · Dec 31, 2025Total Liabilities
33.89MUSDFY2025 · Dec 31, 2025Total Non-current Assets
235.57MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
17.63MUSDFY2025 · Dec 31, 2025Total Current Liabilities
16.25MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
25.52MUSDFY2025 · Dec 31, 2025Other Short-term Investments
28.50MUSDFY2025 · Dec 31, 2025Accounts Receivable
7.39MUSDFY2025 · Dec 31, 2025Accounts Payable
1.88MUSDFY2025 · Dec 31, 2025Short-term Debt
3.88MUSDFY2025 · Dec 31, 2025Deferred Revenue
3.16MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.22MUSDFY2025 · Dec 31, 2025Long-term Debt
16.45MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
393.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-166.18MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
267.03MUSDvs all stocks (USD)
52-Week Low
1.30USDUpdated Jul 19, 202652-Week High
2.79USDUpdated Jul 19, 202652-Week Change
7.07%vs all stocks
Beta
1.17xvs all stocks
50-Day MA
2.27USDUpdated Jul 19, 2026200-Day MA
1.86USDUpdated Jul 19, 2026Avg 10-Day Volume
592.15KSharesUpdated Jul 19, 2026Avg 30-Day Volume
581.74KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.4600USDUpdated Jul 19, 2026Other Income / Expense
15.00KUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: -1.88
Financial Health
Altman Z-Score 4.17: safe zoneNotable
Altman Z-Score: 4.17
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $28.94M, lower than 95% of all stocks globallySignificant
Revenue (USD): 28,939,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tomocube Inc.
Tier 1ProductionApproval-Gated PipelineSenseMaking
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Proteina Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMaking
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Evolus Inc.
Tier 1ProductionApproval-Gated PipelineAttentionInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou Sepax Technologies Inc.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Tactile Systems Technology Inc.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Olaplex Holdings, Inc.
3 interpretationsIntangible ConcentrationGoodwill-Heavy EquityMulti-Year Debt Decrease With Cash Near Total Debt And Equity